Clinical Trials: Find a Clinical Trial

At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.

The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.

Showing 361 - 380 of 495 trials
Title Investigatorsort icon Disease(s)
A Phase Ib/II Study of OMP-59R5 plus Etoposide and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer
[Protocol 13-125]
Pietanza, M. Catherine
  • Lung Cancer, Small Cell
    • Other
A Phase I Study of LDE225 with Etoposide and Cisplatin for the Initial Treatment of Extensive Small Cell Lung Cancer
[Protocol 11-206]
Pietanza, M. Catherine
  • Lung Cancer
  • Lung Cancer, Small Cell
    • Other
A Phase III Study of MEK162 versus Dacarbazine in Patients with Inoperable or Metastatic Melanomas with NRAS Q61 Mutations: The NEMO Trial
[Protocol 13-083]
Postow, Michael
  • Melanoma
A Phase II Study of Nivolumab plus Ipilimumab versus Ipilimumab Alone in Patients with Previously Untreated Inoperable or Metastatic Melanoma
[Protocol 13-169]
Postow, Michael
  • Melanoma
A Phase II Study of LEE011 plus LGX818 in Patients with BRAF-Mutant Melanoma
[Protocol 13-097]
Postow, Michael
  • Melanoma
A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
[Protocol 13-102]
Postow, Michael
  • Melanoma
Expanded Access to MK-3475 for Patients with Metastatic Melanoma with Few to No Treatment Options
[Protocol 14-093]
Postow, Michael
  • Melanoma
A Phase I Study of the NY-ESO-1 Vaccine plus Ipilimumab in Patients with Inoperable or Metastatic Melanoma
[Protocol 12-253]
Postow, Michael
  • Melanoma
A Phase II Study of LGX818 plus a Second Investigational Drug in Patients with Locally Advanced or Metastatic Melanoma that Continued to Grow on LGX818 Alone
[Protocol 13-233]
Postow, Michael
  • Melanoma
Expanded Access of Prochymal Infusion for the Treatment of Pediatric Patients with Acute Refractory GVHD
[Protocol 09-072]
Prockop, Susan
  • Blood and Marrow Transplantation
    • Transplantation
A Study Analyzing Patients Treated for Wiskott-Aldrich Syndrome Since 1990
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-066]
Prockop, Susan
  • Hematology
    • Hematologic Disorders
Development and Validation of a New Patient-Reported Outcome Instrument on the Impact of Altered Facial Appearance Following Oncologic Head and Neck Resection and Reconstruction
[Protocol 07-098]
Pusic, Andrea
  • Head & Neck Cancer
  • Survivorship
Microvascular Reconstruction for Advanced-Stage Head and Neck Cancer Patients: A Prospective Analysis of Quality of Life and Symptom Relief
[Protocol 07-150]
Pusic, Andrea
  • Head & Neck Cancer
  • Quality of Life
Mastectomy Reconstruction Outcomes Consortium (MROC) Study
[Protocol 11-175]
Pusic, Andrea
  • Breast Cancer
  • Survivorship
A Phase II Study of AUY922 in Patients with Myelofibrosis
Newly Diagnosed & Relapsed/Refractory
[Protocol 12-076]
Rampal, Raajit
  • Hematology
    • Hematologic Disorders
    • Hematologic Malignancies
  • Leukemia
    • Myeloproliferative Neoplasm
  • Rare Blood Disorders
A Phase IA/B Study of CC-115 in Castration-Resistant Prostate Cancer
[Protocol 12-080]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase Ib Study of ARN-509 plus Everolimus in Men with Progressive Metastatic Castration-Resistant Prostate Cancer After Abiraterone Therapy
[Protocol 13-025]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer
[Protocol 11-182]
Rathkopf, Dana
  • Prostate Cancer
    • Localized Disease
A Phase II Study of MLN0128 in Men with Castration-Resistant Prostate Cancer
[Protocol 13-143]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase III Study of ARN-509 versus Placebo in Men with Non-Metastatic Castration-Resistant Prostate Cancer
[Protocol 13-243]
Rathkopf, Dana
  • Prostate Cancer
    • Rising PSA After Primary Therapy